The FDA's warnings to Eli Lilly, Novo Nordisk and Hims & Hers spotlight risks for ETFs tied to the weight-loss drug boom.

The purchase by Heartland Food Products comes as sales for the weight loss brand have plummeted, with more consumers turning to GLP-1 medications.

The REACH study included data from 58,336 Medicare patients aged 66 years and older with T2D and ASCVD who had initiated either semaglutide or dulaglutide.

Roughly one out of every two people who start taking semaglutide (Wegovy; Novo Nordisk) to lose weight will stop taking the medication within a year, according to a large population-based study out of ...

Obesity is linked to accelerated aging and early death and is typically defined by body mass index, a measure of weight and ...

Ozempic might not work as well for people who eat their feelings, according to Japanese researchers. Emotional eaters are ...

Over the last six years, three GLP-1 drugs have been approved for children aged 10 and older with type 2 diabetes. | Over the ...

People with a common personality trait practiced by as many as one in five Americans may see fewer lasting results from GLP-1 ...

In recent weeks, several health systems and hospitals have opened new or expanded pharmacies. Editor’s note: This list is not exhaustive. 1. OhioHealth Van Wert Hospital completed its $3.15 million ...